On Nov 01, major Wall Street analysts update their ratings for $Penumbra (PEN.US)$, with price targets ranging from $232 to $248.
Deutsche Bank analyst Pito Chickering maintains with a buy rating, and adjusts the target price from $205 to $241.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $180 to $248.
Needham analyst Michael Matson maintains with a hold rating.
Stifel analyst Mathew Blackman maintains with a buy rating, and maintains the target price at $238.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $234 to $232.
Furthermore, according to the comprehensive report, the opinions of $Penumbra (PEN.US)$'s main analysts recently are as follows:
The company's Q3 earnings surpassed expectations. Enrollment for the THUNDER trial concluded in Q3, and the firm achieved FDA clearance for two new CAVT products, Lightning Bolt 6X and 12. Looking forward, it is anticipated that innovation in a highly under-penetrated market will propel the company's double-digit revenue growth and contribute to significant margin expansion.
The firm's assessment indicates that the third quarter revenue and operating margin exceed expectations, reinforcing belief in the company's ability to meet its revised full-year guidance and in the anticipated growth acceleration for the following year, which is seen as essential for the stock's upward trajectory.
Here are the latest investment ratings and price targets for $Penumbra (PEN.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月1日，多家華爾街大行更新了$Penumbra (PEN.US)$的評級，目標價介於232美元至248美元。
德意志銀行分析師Pito Chickering維持買入評級，並將目標價從205美元上調至241美元。
貝雅分析師David Rescott維持買入評級，並將目標價從180美元上調至248美元。
Needham分析師Michael Matson維持持有評級。
斯迪富分析師Mathew Blackman維持買入評級，維持目標價238美元。
BTIG分析師Ryan Zimmerman維持買入評級，並將目標價從234美元下調至232美元。
此外，綜合報道，$Penumbra (PEN.US)$近期主要分析師觀點如下：
公司在第三季度的營收超出預期。THUNDER試驗的招募已在第三季度結束，公司獲得了兩款新的CAVt產品——Lightning Bolt 6X和12的FDA批准。展望未來，預計在一個高度未滲透的市場創新將推動公司實現兩位數的營業收入增長，並有助於顯著擴大利潤率。
公司的評估表明，第三季度的營業收入和營業利潤率超出預期，進一步確認了對公司能夠實現修訂後全年指引以及對於下一年預期增長加速的信心，這被視爲股票上升軌跡的必要條件。
以下爲今日7位分析師對$Penumbra (PEN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
